Hang Fat Ginseng Holdings Co (0911) fair value: what the stock is really worth
As of Nov 12, 2026: fair value (intrinsic value) of Hang Fat Ginseng Holdings Co stock HK$0.89, price HK$0.30, upside +196.7%, quality 70 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range HK$0.0230 – HK$1.20 · fair‑value band HK$0.6600 – HK$1.16 · the HK$0.3000 price screens below the HK$0.8900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.
Follow Hang Fat Ginseng Holdings Co in your weekly email
Every Wednesday you see whether Hang Fat Ginseng Holdings Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Qianhai Health Holdings Limited, an investment holding company, engages in the trading and sale of electronic components, and health-care products and food businesses in Hong Kong. It offers Chinese herbal medicines and other health care products; and administrative services.
Show moreShow less
The company also sells health beverages, ginseng wine, and skin-care products.
In addition, it is involved in the sale of information technology component products, including NAND flash wafer, a thin slice of semiconductor material, such as silicon, a component of flash memory integrated circuits; and embed multi-chip package memory, an electronic component containing several memory chip and other electronic components.
The company was formerly known as Hang Fat Ginseng Holdings Company Limited and changed its name to Qianhai Health Holdings Limited in September 2016. Qianhai Health Holdings Limited was founded in 1989 and is based in Sheung Wan, Hong Kong.
Qianhai Health Holdings Limited is a subsidiary of Explorer Rosy Limited.
Stock analysis
Hang Fat Ginseng Holdings Co (0911) currently trades at HK$0.3000, while our model-based Fair Value estimate is HK$0.8900, implying the stock looks roughly 66% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$3.38 per share, and 24 of the 24 models we run sit above the HK$0.3000 price.
Bear case: the Earnings-Based group reads lowest at HK$0.6150, and 0 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.6600 (bear) to HK$1.16 (bull), the price of HK$0.3000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hang Fat Ginseng Holdings Co reported revenue of HK$677M in FY2025 versus HK$283M in FY2021, a compound +24.3%/yr. Reported net income was HK$5.9M in FY2025.
Key figures
Market cap HK$50.8M (≈ $6.5M) Micro · P/E ratio 15.8 · P/S ratio 0.14 · Net margin 0.9% · Return on equity 1.0% · Return on assets (EBIT) −7.4% (5-year average) · Operating margin 2.5% · Revenue (TTM) HK$453M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).
What moves the price
The share trades about 75% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 197%, 0911 screens cheaper than that median.
Fair Value models
BearHK$0.6600Fair Value HK$0.8900BullHK$1.16
Price HK$0.3000 · Upside +196.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.39/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+30.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Start year 2020 (pandemic). Over 10 years: −2.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
’12
’13
’14
’15
’16
’17
’19
’20
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−26.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−26.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−26.0% vs −38.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 1%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 12.5%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Hang Fat Ginseng Holdings Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+196.7% · Top 25%
Profitability
Return on equity (12 months)1.0% · Below median
Return on assets1.5% · Below median
Net margin (12 months)0.9% · Below median
Operating margin (12 months)2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−65.7% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hang Fat Ginseng Holdings Co Fair Value". https://www.fairvalue-calculator.com/stock/0911
Frequently asked questions
Is Hang Fat Ginseng Holdings Co (0911) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$0.3000, about +197% upside (undervalued).
What is the fair value of 0911?
Our model-based fair value for Hang Fat Ginseng Holdings Co is HK$0.8900 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$0.3000.
What is the quality score of 0911?
Hang Fat Ginseng Holdings Co has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hang Fat Ginseng Holdings Co (0911)?
Our model-based price target is the fair value of HK$0.8900 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario HK$0.6600, optimistic scenario HK$1.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Hang Fat Ginseng Holdings Co stock forecast for 2026?
Our models put fair value at HK$0.8900, about +197% upside versus a price of HK$0.3000 (undervalued). Cautious scenario HK$0.6600, optimistic scenario HK$1.16. The calculation is refreshed regularly with new filings.
What is the revenue of Hang Fat Ginseng Holdings Co (0911)?
Hang Fat Ginseng Holdings Co reported trailing-twelve-month revenue of about HK$453M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Hang Fat Ginseng Holdings Co (0911)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hang Fat Ginseng Holdings Co it is HK$0.8900 per share (as of Nov 14, 2026), against a price of HK$0.3000. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hang Fat Ginseng Holdings Co stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 0911 trades below its calculated fair value: price HK$0.3000, fair value HK$0.8900, a gap of about +197% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0911?
No. The price is what the market pays today (HK$0.3000); the fair value is what the company's own numbers justify (HK$0.8900). For Hang Fat Ginseng Holdings Co the two are HK$0.5900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hang Fat Ginseng Holdings Co worth?
The market values Hang Fat Ginseng Holdings Co at about HK$50.8M (market capitalisation, as of Nov 14, 2026). Per share that is HK$0.3000; our models calculate a fair value of HK$0.8900 per share.
What do the bullish and bearish scenarios say about 0911?
Our models span a range for Hang Fat Ginseng Holdings Co: cautious scenario HK$0.6600, base HK$0.8900, optimistic HK$1.16 per share (as of Nov 14, 2026, price HK$0.3000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0911?
Hang Fat Ginseng Holdings Co trades at a price-to-earnings ratio of 15.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.8900 is built from several models across several years. Other multiples: P/B 0.1, P/S 0.1.
How solid is the balance sheet of Hang Fat Ginseng Holdings Co (0911)?
Balance-sheet figures for Hang Fat Ginseng Holdings Co (as of Nov 14, 2026): return on equity 1.0%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 0911 from its 52-week high?
Hang Fat Ginseng Holdings Co trades at HK$0.3000, about 75% below its 52-week high of HK$1.20 and 15% above the low of HK$0.2600 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8900 is for.
Which stocks are comparable to Hang Fat Ginseng Holdings Co?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hang Fat Ginseng Holdings Co stock attractive at the current price?
The data as of Nov 14, 2026: price HK$0.3000, calculated fair value HK$0.8900 (+197%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0911 calculated?
We run Hang Fat Ginseng Holdings Co through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.8900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Hang Fat Ginseng Holdings Co currently trades 66% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hang Fat Ginseng Holdings Co (0911)?
The closing price on Nov 12, 2026 was HK$0.3000. Our model-based fair value is HK$0.8900, about +197% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hang Fat Ginseng Holdings Co right now?
The price is below even our cautious bear case (HK$0.6600). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (70/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Hang Fat Ginseng Holdings Co
How large is the market capitalisation of Hang Fat Ginseng Holdings Co (0911)?
The market capitalisation of Hang Fat Ginseng Holdings Co is HK$50.8M (≈ $6.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hang Fat Ginseng Holdings Co (0911)?
The price-to-sales ratio of Hang Fat Ginseng Holdings Co is 0.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Hang Fat Ginseng Holdings Co (0911)?
The net margin of Hang Fat Ginseng Holdings Co is 0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hang Fat Ginseng Holdings Co (0911)?
The return on equity (ROE) of Hang Fat Ginseng Holdings Co is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hang Fat Ginseng Holdings Co (0911)?
On an EBIT basis the return on assets of Hang Fat Ginseng Holdings Co is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hang Fat Ginseng Holdings Co (0911)?
The operating margin of Hang Fat Ginseng Holdings Co is 2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hang Fat Ginseng Holdings Co (0911)?
Revenue at Hang Fat Ginseng Holdings Co is growing −65.7% versus a year earlier (3y avg −29.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hang Fat Ginseng Holdings Co (0911)?
Earnings per share at Hang Fat Ginseng Holdings Co are growing −40.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hang Fat Ginseng Holdings Co (0911) generate?
The free cash flow of Hang Fat Ginseng Holdings Co is HK$38.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Hang Fat Ginseng Holdings Co (0911) hold?
Hang Fat Ginseng Holdings Co holds more cash than debt, HK$61.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hang Fat Ginseng Holdings Co in the live analysis
One click puts Hang Fat Ginseng Holdings Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 14, 2026